EUVIMEDEUVIMED entdecken
Crossref

DNA methylation-mediated epigenetic regulation of oncogenic RPS2 as a novel therapeutic target and biomarker in hepatocellular carcinoma

Batoul Abi Zamer, Bilal Rah, Manju Nidagodu Jayakumar, Wafaa Abumustafa, Mawieh Hamad, Jibran Sualeh Muhammad

Biochemical and Biophysical Research Communications · 2024

DOI: 10.1016/j.bbrc.2023.149453 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Batoul Abi Zamer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates; Research Institute of Medical and He…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: University of Sharjah, King Hussein Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ribosomal Protein S2 (RPS2) has emerged as a potential prognostic biomarker due to its involvement in key cellular processes and its altered expression pattern in certain types of cancer. However, its role in hepatocellular carcinoma (HCC) has yet to be investigated. Herein, we analyzed RPS2 mRNA expression and promoter methylation in HCC patient samples and HepG2 cells. Subsequently, loss-of-function experiments were conducted to determine the function of RPS2 in HCC cells in vitro. Our results revealed that RPS2 mRNA expression is significantly elevated, and its promoter is hypomethylated in HCC patient samples compared to controls. In addition, 5-Azacytidine treatment in HepG2 cells decreased RPS2 promoter methylation level and increased its mRNA expression. RPS2 knockdown in HepG2 cells suppressed cell proliferation and promoted apoptosis. Functional pathway analysis of genes positively and negatively associated with RPS2 expression in HCC showed enrichment in ribosomal biogenesis, translation machinery, cell cycle regulation, and DNA processing. Furthermore, utilizing drug-protein 3D docking, we found that doxorubicin, sorafenib, and 5-Fluorouracil, showed high affinity to the active sites of RPS2, and in vitro treatment with these drugs reduced RPS2 expression. For the first time, we report on DNA methylation-mediated epigenetic regulation of RPS2 and its oncogenic role in HCC. Our findings suggest that RPS2 plays a significant role in the development and progression of HCC, hence its potential prognostic and therapeutic utility. Moreover, as epigenetic changes happen early in cancer development, RPS2 may serve as a potential biomarker for tumor progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansDNA MethylationEpigenesis, GeneticCell Line, TumorRibosomal ProteinsRNA, MessengerBiomarkersGene Expression Regulation, NeoplasticCell Proliferation

Stichwörter der Autor:innen

BiomarkerDNA methylationEpigeneticsHepatocellular carcinomaRibosomal protein S2Therapeutics

Substanzen

ribosomal protein S2Ribosomal ProteinsRNA, MessengerBiomarkersRPS2 protein, human

Autor:innen und Institutionen

  • Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates; Research Institute of Medical and Health Sciences, University of Sharjah, United Arab Emirates.
  • Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
  • Research Institute of Medical and Health Sciences, University of Sharjah, United Arab Emirates; Department of Medical Laboratory Sciences, College of Health Sciences, University of Sharjah, United Arab Emirates.
  • Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates; Research Institute of Medical and Health Sciences, University of Sharjah, United Arab Emirates. Electronic…

Förderung

  • University of Sharjah
  • King Hussein Cancer Foundation

Zitieren

APA

Abi Zamer, B., Rah, B., Jayakumar, M. N., Abumustafa, W., Hamad, M., & Muhammad, J. S. (2024). DNA methylation-mediated epigenetic regulation of oncogenic RPS2 as a novel therapeutic target and biomarker in hepatocellular carcinoma. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.149453

Vancouver

Abi Zamer B, Rah B, Jayakumar MN, Abumustafa W, Hamad M, Muhammad JS. DNA methylation-mediated epigenetic regulation of oncogenic RPS2 as a novel therapeutic target and biomarker in hepatocellular carcinoma. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2023.149453

BibTeX
@article{AbiZamer2024,
  author = {Abi Zamer, Batoul and Rah, Bilal and Jayakumar, Manju Nidagodu and Abumustafa, Wafaa and Hamad, Mawieh and Muhammad, Jibran Sualeh},
  title = {DNA methylation-mediated epigenetic regulation of oncogenic RPS2 as a novel therapeutic target and biomarker in hepatocellular carcinoma},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2024},
  doi = {10.1016/j.bbrc.2023.149453}
}
Kostenlos starten →